Eidos Therapeutics Announces Publication of AG10 Molecular Design in Journal of Medicinal Chemistry

SAN FRANCISCO, Aug. 23, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced publication of the design and preclinical characterization of its lead product candidate, AG10, in the Journal of Medicinal Chemistry. AG10 is designed to prevent progression of transthyretin (TTR) amyloidosis (ATTR) by stabilizing tetrameric TTR in the blood. AG10 is currently […]